Colchicine as an anti-inflammatory and cardioprotective agent

Bibliography

• Nerlekar N, Beale A, Harper RW. Colchicine–a short history of an ancient drug. Med J Aust 2014;201(11):687–8
   PubMed Web of Science ®Google Scholar
• Stockdill G, Dewar AE. Colchicine in chronic lymphocytic leukemia. N Engl J Med 1984;310(9):597
   PubMed Web of Science ®Google Scholar
• Bhat A, Naguwa SM, Cheema GS, Gershwin ME. Colchicine revisited. Ann N Y Acad Sci 2009;1173:766-73
   PubMed Web of Science ®Google Scholar
• Klintschar M, Beham-Schmidt C, Radner H, et al. Colchicine poisoning by accidental ingestion of meadow saffron (Colchicum autumnale): pathological and medicolegal aspects. Forensic Sci Int 1999;106(3):191-200
   PubMed Web of Science ®Google Scholar
• Nuki G, Simkin PA. A concise history of gout and hyperuricemia and their treatment. Arthritis Res Ther 2006;8(Suppl 1):S1
   PubMed Web of Science ®Google Scholar
• Niel E, Scherrmann JM. Colchicine today. Joint Bone Spine 2006;73(6):672-8
   PubMed Web of Science ®Google Scholar
• FDA Approves Colchicine for Acute Gout, Mediterranean Fever. Agency also provides new information to physicians regarding safe use of drug. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm174620.htm [Last accessed 10 June 2015]
   Google Scholar
• Nuki G. Colchicine: its mechanism of action and efficacy in crystal-induced inflammation. Curr Rheumatol Rep 2008;10(3):218-27
   PubMedGoogle Scholar
• Martinon F, Pétrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440(7081):237-41
   PubMed Web of Science ®Google Scholar
• Cronstein BN, Molad Y, Reibman J, et al. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest 1995;96(2):994-1002
   PubMed Web of Science ®Google Scholar
• Chia EW, Grainger R, Harper JL. Colchicine suppresses neutrophil superoxide production in a murine model of gouty arthritis: a rationale for use of low-dose colchicine. Br J Pharmacol 2008;153(6):1288-95
   PubMed Web of Science ®Google Scholar
• Ben-Chetrit E, Levy M. Does the lack of the P-glycoprotein efflux pump in neutrophils explain the efficacy of colchicine in familial Mediterranean fever and other inflammatory diseases? Med Hypotheses 1998;51(5):377-80
   PubMed Web of Science ®Google Scholar
• Kenney DM, Chao FC, Tullis JL, Conneely GS. Colchicine uptake and binding by human platelets. Thromb Diath Haemorrh 1975;34(3):780-94
   PubMedGoogle Scholar
• Dai Y, Li J. Evidence for thrombin-induced human platelet secretion regulated by the cytoskeleton. Shi Yan Sheng Wu Xue Bao 1995;28(3):236-40
   PubMedGoogle Scholar
• Cerecedo D, Stock R, González S, et al. Modification of actin, myosin and tubulin distribution during cytoplasmic granule movements associated with platelet adhesion. Haematologica 2002;87(11):1165-76
   PubMed Web of Science ®Google Scholar
• Clare GC, Troughton RW. Management of constrictive pericarditis in the 21st century. Curr Treat Options Cardiovasc Med 2007;9(6):436-42
   PubMedGoogle Scholar
• Nikolaidis N, Kountouras J, Giouleme O, et al. Colchicine treatment of liver fibrosis. Hepatogastroenterology 2006;53(68):281-5
   PubMed Web of Science ®Google Scholar
• Kershenobich D, Vargas F, Garcia-Tsao G, et al. Colchicine in the treatment of cirrhosis of the liver. N Engl J Med 1988;318(26):1709-13
   PubMed Web of Science ®Google Scholar
• De Socio G, Cerquaglia C, Curigliano V, et al. Association between familial mediterranean fever and retroperitoneal fibrosis: retroperitoneal fibrosis regression after colchicine therapy. Int J Immunopathol Pharmacol 2009;22(2):521-4
   PubMed Web of Science ®Google Scholar
• Noh JW, Kim J, Kim JW. Localized scleroderma: a clinical study at a single center in Korea. Int J Rheum Dis 2013;16(4):437-41
   PubMed Web of Science ®Google Scholar
• Singhal R, Chang SL, Chong E, et al. Colchicine suppresses atrial fibrillation in failing heart. Int J Cardiol 2014;176(3):651-60
   PubMed Web of Science ®Google Scholar
• Fernandes F, Ramires FJ, Ianni BM, et al. Effect of colchicine on myocardial injury induced by Trypanosoma cruzi in experimental Chagas disease. J Card Fail 2012;18(8):654-9
   PubMed Web of Science ®Google Scholar
• Lee FY, Lu HI, Zhen YY, et al. Benefit of combined therapy with nicorandil and colchicine in preventing monocrotaline-induced rat pulmonary arterial hypertension. Eur J Pharm Sci 2013;50(3–4):372-84
   PubMed Web of Science ®Google Scholar
• Ben-Chetrit E, Bergmann S, Sood R. Mechanism of the anti-inflammatory effect of colchicine in rheumatic diseases: a possible new outlook through microarray analysis. Rheumatology (Oxford) 2006;45(3):274-82
   PubMed Web of Science ®Google Scholar
• Tufan A, Babaoglu MO, Akdogan A, et al. Association of drug transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine response in familial Mediterranean fever. J Rheumatol 2007;34(7):1540-4
   PubMed Web of Science ®Google Scholar
• Ferron GM, Rochdi M, Jusko WJ, Scherrmann JM. Oral absorption characteristics and pharmacokinetics of colchicine in healthy volunteers after single and multiple doses. J Clin Pharmacol 1996;36(10):874-83
   PubMed Web of Science ®Google Scholar
• Rochdi M, Sabouraud A, Girre C, et al. Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects. Eur J Clin Pharmacol 1994;46(4):351-4
   PubMed Web of Science ®Google Scholar
• Chappey ON, Niel E, Wautier JL, et al. Colchicine disposition in human leukocytes after single and multiple oral administration. Clin Pharmacol Ther 1993;54(4):360-7
   PubMed Web of Science ®Google Scholar
• Wason S, Faulkner RD, Davis MW. Are dosing adjustments required for colchicine in the elderly compared with younger patients? Adv Ther 2012;29(6):551-61
   PubMed Web of Science ®Google Scholar
• Wason S, Mount D, Faulkner R. Single-dose, open-label study of the differences in pharmacokinetics of colchicine in subjects with renal impairment, including end-stage renal disease. Clin Drug Investig 2014;34(12):845-55
   PubMed Web of Science ®Google Scholar
• Garrouste C, Philipponnet C, Kaysi S, et al. Severe colchicine intoxication in a renal transplant recipient on cyclosporine. Transplant Proc 2012;44(9):2851-2
   PubMed Web of Science ®Google Scholar
• Davis MW, Wason S. Effect of steady-state atorvastatin on the pharmacokinetics of a single dose of colchicine in healthy adults under fasted conditions. Clin Drug Investig 2014;34(4):259-67
   PubMed Web of Science ®Google Scholar
• Terkeltaub RA, Furst DE, Digiacinto JL, et al. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum 2011;63(8):2226-37
   PubMed Web of Science ®Google Scholar
• Ben-Zvi I, Livneh A. Chronic inflammation in FMF: markers, risk factors, outcomes and therapy. Nat Rev Rheumatol 2011;7(2):105-12
   PubMed Web of Science ®Google Scholar
• Aksu K, Keser G. Coexistence of vasculitides with familial Mediterranean fever. Rheumatol Int 2011;31(10):1263-74
   PubMed Web of Science ®Google Scholar
• Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, et al. The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases. Curr Vasc Pharmacol 2010;8(4):437-49
   PubMed Web of Science ®Google Scholar
• Kuloğlu Z, Kansu A, Ustündağ G, et al. An infant with severe refractory Crohn’s disease and homozygous MEFV mutation who dramatically responded to colchicine. Rheumatol Int 2012;32(3):783-5
   PubMed Web of Science ®Google Scholar
• Lidar M, Yonath H, Shechter N, et al. Incomplete response to colchicine in M694V homozygote FMF patients. Autoimmun Rev 2012;12(1):72-6
   PubMed Web of Science ®Google Scholar
• Soriano A, Verecchia E, Afeltra A, et al. IL-1β biological treatment of familial Mediterranean fever. Clin Rev Allergy Immunol 2013;45(1):117-30
   PubMed Web of Science ®Google Scholar
• Goldfinger SE. Colchicine for familial Mediterranean fever. N Engl J Med 1972;287(25):1302
   PubMed Web of Science ®Google Scholar
• Ter Haar N, Lachmann H, Özen S, et al. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis 2013;72(5):678-85
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Wolff SM, Goldfinger SE, et al. Colchicine therapy for familial mediterranean fever. A double-blind trial. N Engl J Med 1974;291(18):934-7
   PubMed Web of Science ®Google Scholar
• Zemer D, Revach M, Pras M, et al. A controlled trial of colchicine in preventing attacks of familial mediterranean fever. N Engl J Med 1974;291(18):932-4
   PubMed Web of Science ®Google Scholar
• Goldstein RC, Schwabe AD. Prophylactic colchicine therapy in familial Mediterranean fever. A controlled, double-blind study. Ann Intern Med 1974;81(6):792-4
   PubMed Web of Science ®Google Scholar
• Zemer D, Pras M, Sohar E, et al. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 1986;314(16):1001-5
   PubMed Web of Science ®Google Scholar
• Adler Y, Finkelstein Y, Guindo J, et al. Colchicine treatment for recurrent pericarditis. A decade of experience. Circulation 1998;97(21):2183-5
   PubMed Web of Science ®Google Scholar
• Kallinich T, Haffner D, Niehues T, et al. Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics 2007;119(2):e474-83
   PubMed Web of Science ®Google Scholar
• Lidar M, Scherrmann JM, Shinar Y, et al. Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization. Semin Arthritis Rheum 2004;33(4):273-82
   PubMed Web of Science ®Google Scholar
• Langevitz P, Livneh A, Neumann L, et al. Prevalence of ischemic heart disease in patients with familial Mediterranean fever. Isr Med Assoc J 2001;3(1):9-12
   PubMed Web of Science ®Google Scholar
• Koca B, Kasapçopur O, Bakari S, et al. QT dispersion and cardiac involvement in children with familial Mediterranean fever. Cardiol Young 2012;22(4):404-9
   PubMed Web of Science ®Google Scholar
• Nussinovitch U, Kaminer K, Nussinovitch M, et al. QT interval variability in familial Mediterranean fever: a study in colchicine-responsive and colchicine-resistant patients. Clin Rheumatol 2012;31(5):795-9
   PubMed Web of Science ®Google Scholar
• Nussinovitch U, Livneh A, Volovitz B, et al. Normal QT dispersion in colchicine-resistant familial Mediterranean fever (FMF). Clin Rheumatol 2012;31(7):1093-6
   PubMed Web of Science ®Google Scholar
• Giese A, Ornek A, Kurucay M, et al. P wave dispersion and QT dispersion in adult Turkish migrants with familial mediterranean fever living in Germany. Int J Med Sci 2014;11(11):1140-6
   PubMed Web of Science ®Google Scholar
• Coban E, Adanir H. Platelet activation in patients with Familial Mediterranean Fever. Platelets 2008;19(6):405-8
   PubMed Web of Science ®Google Scholar
• Abanonu GB, Daskin A, Akdogan MF, et al. Mean platelet volume and β-thromboglobulin levels in familial Mediterranean fever: effect of colchicine use? Eur J Intern Med 2012;23(7):661-4
   PubMed Web of Science ®Google Scholar
• Terekeci HM, Oktenli C, Ozgurtas T, et al. Increased asymmetric dimethylarginine levels in young men with familial Mediterranean fever (FMF): is it early evidence of interaction between inflammation and endothelial dysfunction in FMF? J Rheumatol 2008;35(10):2024-9
   PubMed Web of Science ®Google Scholar
• Pamuk BO, Sari I, Selcuk S, et al. Evaluation of circulating endothelial biomarkers in familial Mediterranean fever. Rheumatol Int 2013;33(8):1967-72
   PubMed Web of Science ®Google Scholar
• La Regina M, Gasparyan AY, Orlandini F, Prisco D. Behçet’s disease as a model of venous thrombosis. Open Cardiovasc Med J 2010;4:71-7
   PubMedGoogle Scholar
• Matsumura N, Mizushima Y. Leucocyte movement and colchicine treatment in Behcet’s disease. Lancet 1975;2(7939):813
   PubMed Web of Science ®Google Scholar
• Mizushima Y, Matsumura N, Mori M, et al. Colchicine in Behçet’s disease. Lancet 1977;2(8046):1037
   PubMed Web of Science ®Google Scholar
• Aktulga E, Altaç M, Müftüoglu A, et al. A double blind study of colchicine in Behçet’s disease. Haematologica 1980;65(3):399-402
   PubMed Web of Science ®Google Scholar
• Yurdakul S, Mat C, Tüzün Y, et al. A double-blind trial of colchicine in Behçet’s syndrome. Arthritis Rheum 2001;44(11):2686-92
   PubMed Web of Science ®Google Scholar
• Saenz A, Ausejo M, Shea B, et al. Pharmacotherapy for Behcet’s syndrome. Cochrane Database Syst Rev 2000(2):CD001084
   PubMedGoogle Scholar
• Geri G, Wechsler B, Thi Huong du L, et al. Spectrum of cardiac lesions in Behçet disease: a series of 52 patients and review of the literature. Medicine (Baltimore) 2012;91(1):25-34
   PubMed Web of Science ®Google Scholar
• Louali FE, Tamdy A, Soufiani A, et al. Cardiac thrombosis as a manifestation of Behçet syndrome. Tex Heart Inst J 2010;37(5):568-71
   PubMed Web of Science ®Google Scholar
• Sacré K, Ducrocq G, Hernigou A, et al. Unusual cardiovascular events in Behçet’s disease. Clin Exp Rheumatol 2010;28(4 Suppl 60):S82-5
   PubMed Web of Science ®Google Scholar
• Yilmaz S, Cimen KA. Pulmonary artery aneurysms in Behçet’s disease. Rheumatol Int 2010;30(10):1401-3
   PubMed Web of Science ®Google Scholar
• Zhuang J, Wang S, Zhang Z, et al. Acute myocardial infarction and ascending aortic aneurysm in a child with Behçet’s disease. Turk J Pediatr 2008;50(1):81-5
   PubMed Web of Science ®Google Scholar
• Kwon CM, Lee SH, Kim JH, et al. A case of Behçet’s disease with pericarditis, thrombotic thrombocytopenic purpura, deep vein thrombosis and coronary artery pseudo aneurysm. Korean J Intern Med 2006;21(1):50-6
   PubMedGoogle Scholar
• Ozen S, Bilginer Y, Besbas N, et al. Behçet disease: treatment of vascular involvement in children. Eur J Pediatr 2010;169(4):427-30
   PubMed Web of Science ®Google Scholar
• Roddy E, Mallen CD, Doherty M. Gout. BMJ 2013;347:f5648
   PubMedGoogle Scholar
• Underwood M. Gout. BMJ Clin Evid 2015;2015
   PubMedGoogle Scholar
• Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 2010;62(4):1060-8
   PubMed Web of Science ®Google Scholar
• Marwah RK. Comorbidities in gouty arthritis. J Investig Med 2011;59(8):1211-20
   PubMed Web of Science ®Google Scholar
• Crittenden DB, Lehmann RA, Schneck L, et al. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatol 2012;39(7):1458-64
   PubMed Web of Science ®Google Scholar
• Paccalin M, Hachulla E, Cazalet C, et al. Localized amyloidosis: a survey of 35 French cases. Amyloid 2005;12(4):239-45
   PubMed Web of Science ®Google Scholar
• Zemer D, Pras M, Sohar E, et al. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 1986;314(16):1001-5
   PubMed Web of Science ®Google Scholar
• Livneh A, Zemer D, Langevitz P, et al. Colchicine treatment of AA amyloidosis of familial Mediterranean fever. An analysis of factors affecting outcome. Arthritis Rheum 1994;37(12):1804-11
   PubMed Web of Science ®Google Scholar
• Skinner M, Anderson J, Simms R, et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 1996;100(3):290-8
   PubMed Web of Science ®Google Scholar
• Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997;336(17):1202-7
   PubMed Web of Science ®Google Scholar
• Abdallah E, Waked E. Incidence and clinical outcome of renal amyloidosis: a retrospective study. Saudi J Kidney Dis Transpl 2013;24(5):950-8
   PubMedGoogle Scholar
• Unverdi S, Inal S, Ceri M, et al. Is colchicine therapy effective in all patients with secondary amyloidosis? Ren Fail 2013;35(8):1071-4
   PubMed Web of Science ®Google Scholar
• Berkun Y, Padeh S, Reichman B, et al. A single testing of serum amyloid a levels as a tool for diagnosis and treatment dilemmas in familial Mediterranean fever. Semin Arthritis Rheum 2007;37(3):182-8
   PubMed Web of Science ®Google Scholar
• Brandwein SR, Sipe JD, Tatsuta E, et al. Colchicine in acute inflammation: stimulation of production of interleukin-1 and modulation of the acute phase serum amyloid A protein response. J Rheumatol 1984;11(5):597-601
   PubMed Web of Science ®Google Scholar
• Nussinovitch U, Nussinovitch N, Nussinovitch M, et al. QT dispersion in amyloidosis due to familial Mediterranean fever. Rheumatol Int 2012;32(7):1945-8
   PubMed Web of Science ®Google Scholar
• Nussinovitch U, Volovitz B, Nussinovitch M, et al. Abnormal heart rate variability in AA amyloidosis of familial Mediterranean fever. Amyloid 2011;18(4):206-10
   PubMed Web of Science ®Google Scholar
• Nussinovitch U, Livneh A, Nussinovitch M, et al. P-wave dispersion in systemic AA amyloidosis of familial Mediterranean fever. Clin Rheumatol 2011;30(10):1295-8
   PubMed Web of Science ®Google Scholar
• Maisch B, Seferović PM, Ristić AD, et al. Guidelines on the diagnosis and management of pericardial diseases executive summary; the task force on the diagnosis and management of pericardial diseases of the European society of cardiology. Eur Heart J 2004;25(7):587-610
   PubMed Web of Science ®Google Scholar
• Alabed S, Cabello JB, Irving GJ, et al. Colchicine for pericarditis. Cochrane Database Syst Rev 2014;8:CD010652
   Google Scholar
• Guindo J, Rodriguez de la Serna A, Ramió J, et al. Recurrent pericarditis. relief with colchicine. Circulation 1990;82(4):1117-20
   PubMed Web of Science ®Google Scholar
• Imazio M, Bobbio M, Cecchi E, et al. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation 2005;112(13):2012-16
   PubMed Web of Science ®Google Scholar
• Imazio M, Brucato A, Cemin R, et al. A randomized trial of colchicine for acute pericarditis. N Engl J Med 2013;369(16):1522-8
   PubMed Web of Science ®Google Scholar
• Imazio M, Bobbio M, Cecchi E, et al. Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial. Arch Intern Med 2005;165(17):1987-91
   PubMed Web of Science ®Google Scholar
• Imazio M, Brucato A, Cemin R, et al. Colchicine for recurrent pericarditis (CORP): a randomized trial. Ann Intern Med 2011;155(7):409-14
   PubMed Web of Science ®Google Scholar
• Imazio M, Belli R, Brucato A, et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet 2014;383(9936):2232-7
   PubMed Web of Science ®Google Scholar
• Imazio M, Brucato A, Ferrazzi P, et al. Colchicine reduces postoperative atrial fibrillation: results of the Colchicine for the teroid-Prevention of the Postpericardiotomy Syndrome (COPPS) atrial fibrillation substudy. Circulation 2011;124(21):2290-5
   PubMed Web of Science ®Google Scholar
• Deftereos S, Giannopoulos G, Kossyvakis C, et al. Colchicine for prevention of early atrial fibrillation recurrence after pulmonary vein isolation: a randomized controlled study. J Am Coll Cardiol 2012;60(18):1790-6
   PubMed Web of Science ®Google Scholar
• Imazio M, Brucato A, Ferrazzi P, et al. Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: the COPPS-2 randomized clinical trial. JAMA 2014;312(10):1016-23
   PubMed Web of Science ®Google Scholar
• Nidorf M, Thompson PL. Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease. Am J Cardiol 2007;99(6):805-7
   PubMed Web of Science ®Google Scholar
• Raju NC, Yi Q, Nidorf M, et al. Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: a pilot randomized controlled trial. J Thromb Thrombolysis 2012;33(1):88-94
   PubMed Web of Science ®Google Scholar
• Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 2013;61(4):404-10
   PubMed Web of Science ®Google Scholar
• Deftereos S, Giannopoulos G, Raisakis K, et al. Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients. J Am Coll Cardiol 2013;61(16):1679-85
   PubMed Web of Science ®Google Scholar
• Deftereos S, Giannopoulos G, Panagopoulou V, et al. Anti-inflammatory treatment with colchicine in stable chronic heart failure: a prospective, randomized study. JACC Heart Fail 2014;2(2):131-7
   PubMed Web of Science ®Google Scholar
• Giannopoulos G, Angelidis C, Kouritas VK, et al. Usefulness of colchicine to reduce perioperative myocardial damage in patients who underwent on-pump coronary artery bypass grafting. Am J Cardiol 2015;115(10):1376-81
   PubMed Web of Science ®Google Scholar
• Padeh S, Gerstein M, Berkun Y. Colchicine is a safe drug in children with familial Mediterranean fever. J Pediatr 2012;161(6):1142-6
   PubMed Web of Science ®Google Scholar
• Todd BA, Billups SJ, Delate T, et al. Assessment of the association between colchicine therapy and serious adverse events. Pharmacotherapy 2012;32(11):974-80
   PubMed Web of Science ®Google Scholar
• Lee KY, Kim do Y, Chang JY, Bang D. Two cases of acute leukopenia induced by colchicine with concurrent immunosuppressants use in Behçet’s disease. Yonsei Med J 2008;49(1):171-3
   PubMed Web of Science ®Google Scholar
• Sarica K, Süzer O, Gürler A, et al. Urological evaluation of Behçet patients and the effect of colchicine on fertility. Eur Urol 1995;27(1):39-42
   PubMed Web of Science ®Google Scholar
• Kirchin VS, Southgate HJ, Beard RC. Colchicine: an unusual cause of reversible azoospermia. BJU Int 1999;83(1):156
   PubMed Web of Science ®Google Scholar
• Finkelstein Y, Aks SE, Hutson JR, et al. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol (Phila) 2010;48(5):407-14
   PubMed Web of Science ®Google Scholar
• Mullins M, Cannarozzi AA, Bailey TC, Ranganathan P. Unrecognized fatalities related to colchicine in hospitalized patients. Clin Toxicol (Phila) 2011;49(7):648-52
   PubMed Web of Science ®Google Scholar
• Komorowski AL, Rodil JM. Emergency abdominal surgery and colchicine overdose. J Emerg Trauma Shock 2012;5(4):342-3
   PubMedGoogle Scholar
• Montiel V, Huberlant V, Vincent MF, et al. Multiple organ failure after an overdose of less than 0.4 mg/kg of colchicine: role of coingestants and drugs during intensive care management. Clin Toxicol (Phila) 2010;48(8):845-8
   PubMed Web of Science ®Google Scholar
• van der Velden W, Huussen J, Ter Laak H, de Sévaux R. Colchicine-induced neuromyopathy in a patient with chronic renal failure: the role of clarithromycin. Neth J Med 2008;66(5):204-6
   PubMed Web of Science ®Google Scholar
• Eleftheriou G, Bacis G, Fiocchi R, Sebastiano R. Colchicine-induced toxicity in a heart transplant patient with chronic renal failure. Clin Toxicol (Phila) 2008;46(9):827-30
   PubMed Web of Science ®Google Scholar
• Bouquié R, Deslandes G, Renaud C, et al. Colchicine-induced rhabdomyolysis in a heart/lung transplant patient with concurrent use of cyclosporin, pravastatin, and azithromycin. J Clin Rheumatol 2011;17(1):28-30
   PubMed Web of Science ®Google Scholar
• Tufan A, Dede DS, Cavus S, et al. Rhabdomyolysis in a patient treated with colchicine and atorvastatin. Ann Pharmacother 2006;40(7–8):1466-9
   PubMed Web of Science ®Google Scholar
• Cantarini L, Volpi N, Galeazzi M, et al. Colchicine myopathy and neuromyopathy: two cases with different characteristics. J Clin Rheumatol 2010;16(5):229-32
   PubMed Web of Science ®Google Scholar
• Gaze DC, Collinson PO. Cardiac troponins as biomarkers of drug- and toxin-induced cardiac toxicity and cardioprotection. Expert Opin Drug Metab Toxicol 2005;1(4):715-25
   PubMedGoogle Scholar
• van Heyningen C, Watson ID. Troponin for prediction of cardiovascular collapse in acute colchicine overdose. Emerg Med J 2005;22(8):599-600
   PubMed Web of Science ®Google Scholar
• Miller MA, Hung YM, Haller C, et al. Colchicine-related death presenting as an unknown case of multiple organ failure. J Emerg Med 2005;28(4):445-8
   PubMed Web of Science ®Google Scholar
• Abodunde OA, LevakaVeera RR, Desai R, et al. Colchicine toxicity precipitated by interaction with sunitinib. J Clin Pharm Ther 2013;38(3):243-5
   PubMed Web of Science ®Google Scholar
• McIntyre IM, Ruszkiewicz AR, Crump K, Drummer OH. Death following colchicine poisoning. J Forensic Sci 1994;39(1):280-6
   PubMed Web of Science ®Google Scholar
• Dickinson M, Juneja S. Haematological toxicity of colchicine. Br J Haematol 2009;146(5):465
   PubMedGoogle Scholar
• Aghabiklooei A, Zamani N, Hassanian-Moghaddam H, et al. Acute colchicine overdose: report of three cases. Reumatismo 2014;65(6):307-11
   PubMedGoogle Scholar
• Bonnel RA, Villalba ML, Karwoski CB, Beitz J. Deaths associated with inappropriate intravenous colchicine administration. J Emerg Med 2002;22(4):385-7
   PubMed Web of Science ®Google Scholar
• Ridker PM, Lüscher TF. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J 2014;35(27):1782-91
   PubMed Web of Science ®Google Scholar
• Sève P, Stankovic K, Broussolle C. Effectiveness of colchicine in a case of recurrent compressive rheumatoid pericarditis. Rheumatol Int 2005;25(7):558-61
   PubMed Web of Science ®Google Scholar
• Mordi I, Tzemos N. Assessing the anti-inflammatory and anti-fibrotic pericardial properties of colchicine in acute pericarditis with cardiovascular magnetic resonance serial imaging. Int J Cardiovasc Imaging 2015;31(5):1033-5
   PubMed Web of Science ®Google Scholar
• Goldfinger S. A randomized trial of colchicine for acute pericarditis. N Engl J Med 2014;370(8):780
   PubMed Web of Science ®Google Scholar
• Crielaard BJ, van der Wal S, Lammers T, et al. A polymeric colchicinoid prodrug with reduced toxicity and improved efficacy for vascular disruption in cancer therapy. Int J Nanomedicine 2011;6:2697-703
   PubMed Web of Science ®Google Scholar
• Crielaard BJ, van der Wal S, Le HT, et al. Liposomes as carriers for colchicine-derived prodrugs: vascular disrupting nanomedicines with tailorable drug release kinetics. Eur J Pharm Sci 2012;45(4):429-35
   PubMed Web of Science ®Google Scholar